Ex Parte ROBINSON et al - Page 2


                 Appeal No.  2001-2316                                               Page       2                    
                 Application No.  08/187,879                                                                            
                        Claim 44 is illustrative of the subject matter on appeal and is reproduced                      
                 below:                                                                                                 
                        44. A method of immunizing a mammal against an immunodeficiency                                 
                             virus of interest selected from the group consisting of: simian                            
                             immunodeficiency virus and human immunodeficiency virus, said                              
                             method comprising administering to the mammal a DNA transcription                          
                             unit comprising DNA encoding an antigen of said immunodeficiency                           
                             virus of interest operatively linked to DNA which is a promoter region,                    
                             in a physiologically acceptable carrier, wherein the DNA transcription                     
                             unit is expressed in cells of the vertebrate, whereby the mammal is                        
                             protected from disease caused by said immunodeficiency virus of                            
                             interest.                                                                                  
                        The references relied upon by the examiner are:                                                 
                 Rekosh et al. (Rekosh), “Coexpression of human immunodeficiency virus                                  
                 envelope proteins and tat from a single simian virus 40 late replacement vector,”                      
                 Proc. Natl. Acad. Sci., Vol. 85, pp. 334-338 (1988)                                                    
                 Hoffenback et al. (Hoffenback), “Unusually high frequencies of HIV-specific                            
                 cytotoxic T lymphocytes in humans,” J. Immunology, Vol. 142, pp. 452-462                               
                 (1989)                                                                                                 
                 Johnson et al. (Johnson), “SIV Infection of Macaques as a Model for AIDS                               
                 Pathogenesis,” Intern. Rev. Immunol., Vol. 8, pp. 55-63 (1992)                                         
                 (Kuby), Immunology p. 477 (Janis Kuby, ed., W.H. Freeman and Co., New York)                            
                 (1992)                                                                                                 
                 Tang et al. (Tang), “Genetic immunization is a simple method for eliciting an                          
                 immune response,” Nature, Vol. 356, pp. 152-154 (1992)                                                 
                 Haynes, “Scientific and social issues of human immunodeficiency virus vaccine                          
                 development,” Science, Vol. 260, pp. 1279-1286 (1993)                                                  
                 Butini et al. (Butini), “Comparative analysis of HIV-specific CTL activity in                          
                 lymphoid tissue and peripheral blood,” J. Cellular Biochem., Suppl. 18B:147 Abst.                      
                 No. J306 (1994)                                                                                        
                 Gilboa et al. (Gilboa), “Gene therapy for infectious diseases: the AIDS model,”                        
                 TIG, Vol. 10, No. 4, pp. 139-144 (1994)                                                                
                 Glaser, “Biotech firms shift focus toward therapeutic HIV vaccine development,”                        
                 Genetic Engineering News, p. 6 (January 1, 1996)                                                       






Page:  Previous  1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  Next 

Last modified: November 3, 2007